Wednesday's ETF Movers: RSSL, RODM
ETF Performance: The Hartford Multifactor Developed Markets ETF is underperforming, down approximately 2.4% in Wednesday afternoon trading, with GSK and GIB shares each declining by about 1.3%.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Analyst Views on RSSL
No data
About the author
Russell 2000 Outperforms S&P 500 in Last 6 Months: Attention on ETFs
Small-Cap Stocks Performance: Small-cap U.S. stocks, represented by the iShares Russell 2000 ETF, have gained about 28% over the past six months, outperforming the S&P 500 ETF's 23% gain, with the Russell 2000 recently surpassing 2,500 for the first time.
Economic Factors Influencing Small Caps: A recent increase in the annual inflation rate to 3% and expectations of further rate cuts by the Federal Reserve may provide a favorable environment for small-cap stocks, especially as trade tensions ease.
Valuation of Small Caps: The Russell 2000 is currently trading at a P/E ratio of 34.32, indicating that small-cap stocks may be overvalued compared to the Nasdaq 100 and S&P 500, which have lower P/E ratios.
Top Performing Small-Cap ETFs: Several small-cap ETFs have shown strong performance, including Fidelity Enhanced Small Cap ETF (up 31.49%) and Vanguard Russell 2000 ETF (up 29.4%), making them attractive options for investors.
RSSL's Underlying Holdings Imply 20% Gain Potential
ETF Analyst Target Price: The Global X Russell 2000 ETF (RSSL) has an implied analyst target price of $106.31, indicating a potential upside of 19.90% from its current trading price of $88.66.
Notable Holdings with Upside: Key underlying holdings such as U S GoldMining Inc, Actuate Therapeutics Inc, and Bright Minds Biosciences Inc show significant upside potential, with expected increases of 235.87%, 231.72%, and 221.06% respectively, compared to their recent share prices.
Wednesday's ETF Movers: RSSL, RODM
ETF Performance: The Hartford Multifactor Developed Markets ETF is underperforming, down approximately 2.4% in Wednesday afternoon trading, with GSK and GIB shares each declining by about 1.3%.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
Russell 2000 Outperforms S&P 500 in Last 6 Months: Attention on ETFs
Small-Cap Stocks Performance: Small-cap U.S. stocks, represented by the iShares Russell 2000 ETF, have gained about 28% over the past six months, outperforming the S&P 500 ETF's 23% gain, with the Russell 2000 recently surpassing 2,500 for the first time.
Economic Factors Influencing Small Caps: A recent increase in the annual inflation rate to 3% and expectations of further rate cuts by the Federal Reserve may provide a favorable environment for small-cap stocks, especially as trade tensions ease.
Valuation of Small Caps: The Russell 2000 is currently trading at a P/E ratio of 34.32, indicating that small-cap stocks may be overvalued compared to the Nasdaq 100 and S&P 500, which have lower P/E ratios.
Top Performing Small-Cap ETFs: Several small-cap ETFs have shown strong performance, including Fidelity Enhanced Small Cap ETF (up 31.49%) and Vanguard Russell 2000 ETF (up 29.4%), making them attractive options for investors.
RSSL's Underlying Holdings Imply 20% Gain Potential
ETF Analyst Target Price: The Global X Russell 2000 ETF (RSSL) has an implied analyst target price of $106.31, indicating a potential upside of 19.90% from its current trading price of $88.66.
Notable Holdings with Upside: Key underlying holdings such as U S GoldMining Inc, Actuate Therapeutics Inc, and Bright Minds Biosciences Inc show significant upside potential, with expected increases of 235.87%, 231.72%, and 221.06% respectively, compared to their recent share prices.
Wednesday's ETF Movers: RSSL, RODM
ETF Performance: The Hartford Multifactor Developed Markets ETF is underperforming, down approximately 2.4% in Wednesday afternoon trading, with GSK and GIB shares each declining by about 1.3%.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
